|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...1920212223242526272829...3940» |
- clozapine / Generic mfg.
Trial completion: DWCZP-I-1: A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril (clinicaltrials.gov) - Feb 12, 2014
P1, N=28, Completed, Sponsor: Dong Wha Pharmaceutical Co. Ltd.
Enrolling by invitation --> Completed
- |||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia (clinicaltrials.gov) - Feb 12, 2014
P4, N=212, Completed, Sponsor: Johnson & Johnson Pte Ltd
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- New P2 trial: Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia (clinicaltrials.gov) - Feb 11, 2014
P2, N=20, Not yet recruiting, Sponsor: Federal University of Rio Grande do Sul
- |||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations (clinicaltrials.gov) - Feb 10, 2014
P4, N=1066, Completed, Sponsor: Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- lurasidone / Generic mfg.
Enrollment closed: Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents (clinicaltrials.gov) - Feb 6, 2014
P2, N=30, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Risperdal Consta (risperidone depot formulation) / J&J
Trial initiation date: An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Feb 5, 2014
P4, N=75, Completed, Sponsor: Janssen Korea, Ltd., Korea
Recruiting --> Active, not recruiting Initiation date: Aug 2007 --> Dec 2007
- || quetiapine extended-release / Generic mfg.
Enrollment change: General Practice Research Database Seroquel XR Safety Study (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=37372, Completed, Sponsor: AstraZeneca
Initiation date: Aug 2007 --> Dec 2007 N=11700 --> 37372
- ||| Risperdal Consta (risperidone depot formulation) / J&J
Enrollment change: An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Feb 5, 2014
P4, N=75, Completed, Sponsor: Janssen Korea, Ltd., Korea
N=11700 --> 37372 N=50 --> 75
- ||| quetiapine extended-release / Generic mfg.
Trial completion: General Practice Research Database Seroquel XR Safety Study (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=37372, Completed, Sponsor: AstraZeneca
N=50 --> 75 Recruiting --> Completed
- || quetiapine extended-release / Generic mfg.
Enrollment closed: Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study (clinicaltrials.gov) - Feb 4, 2014
P=N/A, N=1400, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Enrollment change: Shared Decision Making for Patients With First-admission Schizophrenia (clinicaltrials.gov) - Feb 3, 2014
P2/3, N=52, Recruiting, Sponsor: Yokohama City University
Recruiting --> Active, not recruiting N=100 --> 52
- | Rykindo (risperidone extended release microspheres) / Luye Group
New P1 trial: LY03004SAD: Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Feb 3, 2014
P1, N=32, Recruiting, Sponsor: Luye Pharma Group Ltd.
- ||||||| Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J
Trial completion: PALMFlexS: Paliperidone Palmitate Flexible Dosing in Schizophrenia (clinicaltrials.gov) - Feb 3, 2014
P3, N=1044, Completed, Sponsor: Janssen-Cilag International NV
N=100 --> 52 Active, not recruiting --> Completed
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial: Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia (clinicaltrials.gov) - Feb 2, 2014
P3, N=81, Not yet recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Rykindo (risperidone extended release microspheres) / Luye Group
Enrollment open: LY03004SAD: Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Feb 2, 2014
P1, N=32, Recruiting, Sponsor: Luye Pharma Group Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated (clinicaltrials.gov) - Feb 2, 2014
P4, N=453, Completed, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Vabicaserin (PF-05208769) / Pfizer
Trial completion: Study Evaluating Vabicaserin in Subjects With Schizophrenia (clinicaltrials.gov) - Feb 2, 2014
P2, N=199, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Terminated --> Completed
- Enrollment change: Prevalence of Dissociative Disorders in Children (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=301, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Terminated --> Completed N=3360 --> 301
- Trial completion: Prevalence of Dissociative Disorders in Children (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=301, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
N=3360 --> 301 Recruiting --> Completed
- Arvisol (cannabidiol CR) / Echo Pharma
New P1 trial: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Jan 29, 2014
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
- Arvisol (cannabidiol CR) / Echo Pharma
Enrollment open: CBD-IS: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study (clinicaltrials.gov) - Jan 29, 2014
P1, N=74, Recruiting, Sponsor: Central Institute of Mental Health, Mannheim
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed: EXERCISE-II: Enhancing Synaptic Plasticity and Cognition in Schizophrenia (clinicaltrials.gov) - Jan 27, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: University Medical Center Goettingen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || quetiapine extended-release / Generic mfg.
Trial initiation date: Physician Survey on Monitoring of Patients Treated With Quetiapine (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=800, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Initiation date: Mar 2013 --> Jun 2013
- || Enrollment change: EMR Data to Assess Monitoring of Patients Treated With Quetiapine (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=6153, Completed, Sponsor: AstraZeneca
Initiation date: Mar 2013 --> Jun 2013 N=600 --> 6153
- ||| quetiapine extended-release / Generic mfg.
Trial completion: Physician Survey on Monitoring of Patients Treated With Quetiapine (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=800, Completed, Sponsor: AstraZeneca
N=600 --> 6153 Not yet recruiting --> Completed
- ||| Trial completion: EMR Data to Assess Monitoring of Patients Treated With Quetiapine (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=6153, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Completed Not yet recruiting --> Completed
- ||||||| Trial completion: Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate (clinicaltrials.gov) - Jan 26, 2014
P3, N=142, Completed, Sponsor: Janssen-Cilag Farmaceutica Ltda.
Not yet recruiting --> Completed Recruiting --> Completed
- Enrollment closed: OPUSII: Extended Specialized Assertive Intervention for First Episode Psychosis (clinicaltrials.gov) - Jan 23, 2014
P=N/A, N=400, Active, not recruiting, Sponsor: University of Copenhagen
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
Enrollment closed: PRISMA-1: Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM (clinicaltrials.gov) - Jan 19, 2014
P1, N=33, Active, not recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Chantix (varenicline) / Pfizer
Enrollment open: VAR-PAS: Effects of Varenicline on Plasticity in Schizophrenia (clinicaltrials.gov) - Jan 15, 2014
P2, N=28, Recruiting, Sponsor: Centre for Addiction and Mental Health
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- EVP6308 / Forum Pharmaceuticals
New P1 trial: Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics (clinicaltrials.gov) - Jan 13, 2014
P1, N=40, Not yet recruiting, Sponsor: FORUM Pharmaceuticals Inc
- ||||| Nuplazid (pimavanserin) / Acadia Pharma
New P2 trial: A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (clinicaltrials.gov) - Jan 12, 2014
P2, N=212, Recruiting, Sponsor: ACADIA Pharmaceuticals Inc.
- Trial completion: RIFPP: Risk Factors for Postpartum Psychosis (clinicaltrials.gov) - Jan 10, 2014
P=N/A, N=4000, Completed, Sponsor: Nanjing Medical University
Not yet recruiting --> Recruiting Recruiting --> Completed
- Actemra IV (tocilizumab) / Roche, JW Pharma
New P4 trial: Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia (clinicaltrials.gov) - Jan 9, 2014
P4, N=50, Recruiting, Sponsor: New York State Psychiatric Institute
- olanzapine / Generic mfg.
Trial termination: Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=68, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Active, not recruiting --> Terminated
- Clinical: Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=120, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
- |||| amisulpride / Generic mfg.
Trial completion: Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia (clinicaltrials.gov) - Jan 6, 2014
P4, N=304, Completed, Sponsor: Sanofi
Active, not recruiting --> Terminated Recruiting --> Completed
- Trial completion: Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia (clinicaltrials.gov) - Jan 6, 2014
P=N/A, N=65, Completed, Sponsor: Sheppard Pratt Health System
Recruiting --> Completed Enrolling by invitation --> Completed
- Enrollment change: Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland (clinicaltrials.gov) - Jan 5, 2014
P=N/A, N=62, Completed, Sponsor: University Hospital of North Norway
Enrolling by invitation --> Completed N=120 --> 62
- RO5545965 / Roche
Enrollment open: A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone (clinicaltrials.gov) - Jan 5, 2014
P1, N=48, Recruiting, Sponsor: Hoffmann-La Roche
N=120 --> 62 Not yet recruiting --> Recruiting
- Trial completion: Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland (clinicaltrials.gov) - Jan 5, 2014
P=N/A, N=62, Completed, Sponsor: University Hospital of North Norway
Not yet recruiting --> Recruiting Recruiting --> Completed
- New P2 trial: Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial. (clinicaltrials.gov) - Jan 1, 2014
P2, N=0, Withdrawn, Sponsor: Niuvanniemi Hospital
- | Enrollment closed: Cognitive-Behavioral Therapy in Veterans With Schizophrenia (clinicaltrials.gov) - Jan 1, 2014
P3, N=122, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Recruiting --> Active, not recruiting
- ziprasidone / Generic mfg.
Enrollment change: Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD) (clinicaltrials.gov) - Dec 29, 2013
P=N/A, N=45, Completed, Sponsor: Sheba Medical Center
Recruiting --> Active, not recruiting N=60 --> 45
- ziprasidone / Generic mfg.
Trial completion: Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD) (clinicaltrials.gov) - Dec 29, 2013
P=N/A, N=45, Completed, Sponsor: Sheba Medical Center
N=60 --> 45 Active, not recruiting --> Completed
- Enrollment change, MRI: Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI) (clinicaltrials.gov) - Dec 28, 2013
P=N/A, N=52, Completed, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed N=40 --> 52
- Trial completion, MRI: Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI) (clinicaltrials.gov) - Dec 28, 2013
P=N/A, N=52, Completed, Sponsor: Medical University of Vienna
N=40 --> 52 Recruiting --> Completed
- Enrollment change: CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness (clinicaltrials.gov) - Dec 22, 2013
P=N/A, N=9500, Recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed N=18000 --> 9500
- | New P2 trial: Very Low Nicotine Cigarettes in Smokers With Schizophrenia (clinicaltrials.gov) - Dec 22, 2013
P2, N=80, Not yet recruiting, Sponsor: Brown University
- | RO5545965 / Roche
New P1 trial: A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone (clinicaltrials.gov) - Dec 22, 2013
P1, N=48, Recruiting, Sponsor: Hoffmann-La Roche